Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Acquires 9,985 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Gladden bought 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. This represents a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

DENTSPLY SIRONA Price Performance

XRAY traded up $0.05 during midday trading on Monday, reaching $10.14. 2,937,234 shares of the company’s stock were exchanged, compared to its average volume of 4,807,820. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -3.22, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a one year low of $9.40 and a one year high of $17.09. The business has a 50-day simple moving average of $10.98 and a two-hundred day simple moving average of $11.71.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, research analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of XRAY. Southpoint Capital Advisors LP bought a new position in shares of DENTSPLY SIRONA in the first quarter valued at approximately $116,000,000. AQR Capital Management LLC raised its stake in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after acquiring an additional 6,970,086 shares during the last quarter. Armistice Capital LLC raised its stake in shares of DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after acquiring an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of DENTSPLY SIRONA by 662.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after acquiring an additional 4,003,606 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on XRAY shares. Barclays cut their price target on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their target price for the stock from $13.00 to $17.00 in a report on Thursday, February 19th. Wells Fargo & Company upped their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Zacks Research raised shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Mizuho cut their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, DENTSPLY SIRONA has an average rating of “Hold” and an average target price of $13.55.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.